[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352038-105":59,"doc-detail-352038-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-evidence-for-oncology-patients-with-rare-ntrk-gene-fusions-final-results-from-the-german-multicenter-patient-cohort-study-realtrk","Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions - Final Results From the German Multicenter Patient Cohort Study REALTRK","","TRK inhibitors (TRKis) have reshaped treatment for neurotrophic tyrosine receptor kinase (NTRK) gene fusion–positive tumors, but approvals have relied mainly on small pooled single-arm trials. The REALTRK registry documents real-world molecular testing, treatment patterns, and clinical outcomes for adults with NTRK fusion cancers in Germany and Switzerland. In 47 included patients, TRKi use, response, and survival outcomes were evaluated after validated NTRK fusion diagnosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-evidence-for-oncology-patients-with-rare-ntrk-gene-fusions-final-results-from-the-german-multicenter-patient-cohort-study-realtrk/352038/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-evidence-for-oncology-patients-with-rare-ntrk-gene-fusions-final-results-from-the-german-multicenter-patient-cohort-study-realtrk/352038.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of the REALTRK registry?","Question",{"text":112,"@type":113},"The REALTRK registry characterizes real-world diagnostic approaches, treatment patterns, effectiveness, and safety in adults with NTRK fusion–positive advanced solid tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were NTRK fusions diagnosed and which populations were included?",{"text":117,"@type":113},"Adults with advanced solid tumors from Germany and Switzerland were included, and NTRK fusions had to be diagnosed using validated assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main effectiveness outcomes after TRKi therapy in the study?",{"text":121,"@type":113},"About half of patients responded as the first treatment line after NTRK fusion diagnosis, with an overall response rate of 46.2% and a disease control rate of 73.1%; median progression-free survival was 15.7 months and overall survival 27.6 months in TRKi-treated patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352038,1790185803,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Reports | Precision Medicine  \nReal-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK  \nKarin Potthoff, Dr med1  ; Sebastian Lange, Dr med2,3  ; Thomas Seufferlein, Dr med4  ; Kathrin Heinrich, Dr med5  ; Rainer Claus, Dr med6  ; Annalen Bleckmann, Dr med7  ; Matthias Zaiss, Dr med8; Corinne Vannier, Dr1; Sina Grebhardt, Dr9; Sophie Koszinowski, Dr1;  \nLarissa E. Hillebrand, Dr1; Kai Ringwald, Dr10  ; and Benjamin Kasenda, PD, Dr med11  \nDOI [https://doi.org/10.1200/PO-26-00283](https://doi.org/10.1200/PO-26-00283)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | TRK inhibitors (TRKis) have transformed the therapeutic landscape for patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusion–positive tumors. However, approval of TRKis is based on evidence derived mainly from small, pooled, single-arm clinical trial cohorts. The REALTRK registry aims to describe real-world molecular diagnostic practices, treatment patterns, and clinical outcomes for adult patients with NTRK fusion–positive cancers. |\n| PATIENTS AND METHODS | The REALTRK registry was a multicenter cohort study that included adults with advanced solid tumors harboring NTRK1/2/3 fusions, from Germany and Switzerland. Both retrospective and prospective data were collected from diverse clinical settings. NTRK fusions had to be diagnosed via validated assays. |\n| RESULTS | Of 88 patients screened, 47 adults with advanced NTRK fusion–positive solid tumors were included in the full analysis set. Across all treatment lines after NTRK fusion diagnosis, 29 patients received TRKi therapy, eight received nonTRKi therapy, and 10 received no therapy. Lung cancer, colorectal cancer, and soft tissue sarcoma were the most common tumor types. Next-generation sequencing was the primary diagnostic method, with a median turnaround time of 2 weeks. After NTRK fusion diagnosis, TRKi therapy was immediately initiated in 26 patients, of whom 13 received TRKi as ﬁrst-line treatment in the advanced/metastatic setting. About half of the patients responded to TRKi treatment as the ﬁrst treatment line after NTRK fusion diagnosis (46.2%), with an overall response rate of 46.2% and a disease control rate of 73.1% . The median progression-free survival was 15.7 months, and the overall survival was 27.6 months in TRKi-treated patients. |\n| CONCLUSION | The REALTRK registry provides important real-world insights into the patient path of adult patients with locally advanced or metastatic solid tumors harboring NTRK1/2/3 gene fusions. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted June 10, 2026 Published August 4, 2026  \nJCO Precis Oncol 10:e2600283 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nNeurotrophic tyrosine receptor kinase (NTRK) gene fusions, involving the NTRK1, NTRK2 , or NTRK3 genes, are wellestablished oncogenic drivers across a wide range of cancers. These fusions result in the formation of constitutively active TRK fusion proteins, which promote ligandindependent activation of downstream signaling pathways, driving tumor growth and survival. While NTRK fusions are rare in most cancers, with an estimated prevalence of 0.1% - 0.3% in common malignancies such as colorectal, pancreatic, lung, or breast cancer, they are found with much higher frequencies in certain rare tumor types such as congenital  \nﬁbrosarcoma, salivary gland cancer, and secretory breast carcinoma.1,2  \nTRK inhibitors (TRKis), such as larotrectinib and entrectinib, which are ﬁrst-generation TRKis with activity against TRKA, B, and C, have demonstrated remarkable efﬁcacy in patients with NTRK fusion–positive tumors3 as they both have shown high response rates, durable clinical activity across tumor types, and favorable safety proﬁles, resulting in tumoragnostic approvals in Europe.4 ,5 However, these approvals were based on poo","cbCaic2DpxuCZKE6","https://ap.wps.com/l/cbCaic2DpxuCZKE6","pdf",2649286,16,"English","# Abstract\n## Purpose\n## Patients and Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What is the purpose of the REALTRK registry?\",\"answer\":\"The REALTRK registry characterizes real-world diagnostic approaches, treatment patterns, effectiveness, and safety in adults with NTRK fusion–positive advanced solid tumors.\"},{\"question\":\"How were NTRK fusions diagnosed and which populations were included?\",\"answer\":\"Adults with advanced solid tumors from Germany and Switzerland were included, and NTRK fusions had to be diagnosed using validated assays.\"},{\"question\":\"What were the main effectiveness outcomes after TRKi therapy in the study?\",\"answer\":\"About half of patients responded as the first treatment line after NTRK fusion diagnosis, with an overall response rate of 46.2% and a disease control rate of 73.1%; median progression-free survival was 15.7 months and overall survival 27.6 months in TRKi-treated patients.\"}]","Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions - Final Results From the German Multicenter Patient Cohort Study REALTRK | PDF",1790097320,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/992a0590333757559a666527e2204ff6.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c34976ffc3bb965301a104526ceafadf.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/008858ac2d5d9d9dd481237d3ab9fe58.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12430c3a5313e9e957e7db9f99df6637.webp",980,1311]